Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Case report

Empagliflozin/testosterone/testosterone-cipionate

Erythrocytosis: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Schumacher K. Abstract #1152223: Hereditary Hemochromatosis Gene Mutation in Patients Developing Erythrocytosis on Combined Testosterone Replacement and SGLT-2 Inhibitor Therapy: A Case Series. Endocrine Practice 28 (Suppl.): S19-S20 abstr. 1152223, No. 5, May 2022. Available from: URL: http://doi.org/10.1016/j.eprac.2022.03.062 [abstract] Schumacher K. Abstract #1152223: Hereditary Hemochromatosis Gene Mutation in Patients Developing Erythrocytosis on Combined Testosterone Replacement and SGLT-2 Inhibitor Therapy: A Case Series. Endocrine Practice 28 (Suppl.): S19-S20 abstr. 1152223, No. 5, May 2022. Available from: URL: http://​doi.​org/​10.​1016/​j.​eprac.​2022.​03.​062 [abstract]
Metadaten
Titel
Empagliflozin/testosterone/testosterone-cipionate
Erythrocytosis: 3 case reports
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-15975-z

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Midazolam

Case report

Apixaban